×
About 2,505 results

ALLMedicine™ Adenoid Cystic Carcinoma Center

Research & Reviews  922 results

Combined all-trans retinoic acid with low-dose apatinib in treatment of recurrent/metas...
https://doi.org/10.1002/cam4.5653
Cancer Medicine; Ye L, Zhang L et. al.

Feb 4th, 2023 - Treatment options are limited for recurrent/metastatic adenoid cystic carcinoma of the head and neck (R/M ACCHN). We aimed to evaluate the preliminary results of the efficacy and safety of all-trans retinoic acid (ATRA) combined with low-dose apat...

Dome-Shaped Periorbital Papule
https://www.mdedge.com/dermatology/article/261015/dermatopathology/dome-shaped-periorbital-papule
Adaora Ewulu, BS, Benjamin Tran, MD et. al.

Feb 3rd, 2023 - The Diagnosis: Endocrine Mucin-Producing Sweat Gland Carcinoma Endocrine mucin-producing sweat gland carcinoma (EMPSGC) is a rare cutaneous adnexal tumor that characteristically presents as slowgrowing, flesh-colored papules, nodules, or cystic le.

The Role of Induction Therapy for Sinonasal Cancers.
https://doi.org/10.1007/s11864-022-01046-z
Current Treatment Options in Oncology; Kong KA, Thorp BD et. al.

Jan 26th, 2023 - The role of induction chemotherapy in sinonasal cancers is promising; however, prospective studies with higher grades of evidence are needed. With the currently available literature, the authors would advocate for the use of induction chemotherapy...

A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03999684

Jan 23rd, 2023 - This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being ...

Systemic and Targeted Therapies in Adenoid Cystic Carcinoma.
https://doi.org/10.1007/s11864-022-01043-2
Current Treatment Options in Oncology; Kacew AJ, Hanna GJ

Jan 14th, 2023 - Adenoid cystic carcinoma (ACC) is an often-indolent type of salivary gland cancer (SGC). A subset of patients develops progression or aggressive disease warranting systemic therapy in the recurrent/metastatic (R/M) setting. We recommend genomic te...

see more →

Clinicaltrials.gov  44 results

A Trial of All-trans Retinoic Acid (ATRA) in Advanced Adenoid Cystic Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03999684

Jan 23rd, 2023 - This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being ...

Study of E7389 Liposomal Formulation in Participants With Solid Tumor
https://clinicaltrials.gov/ct2/show/NCT03207672

Nov 29th, 2022 - The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in par...

Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03990571

Nov 9th, 2022 - PRIMARY OBJECTIVES: I. Assess the objective response rate (ORR) to axitinib and avelumab combination according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria patients with recurrent or metastatic adenoid cystic carcinoma (AC...

Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation
https://clinicaltrials.gov/ct2/show/NCT04214366

Nov 1st, 2022 - Adenoid cystic tumors are rare tumors of the head and neck region. Despite their slow growth, re-irradiation is often necessary due to the high metastatic risk. Patients are usually irradiated with photons or, as here at the Heidelberg University ...

Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
https://clinicaltrials.gov/ct2/show/NCT04209660

Oct 28th, 2022 - The purpose of this study is to see if the study drugs, lenvatinib and pembrolizumab, are effective in treating advanced Adenoid Cystic Carcinoma (ACC) or other salivary gland cancers that have come back and/or spread to other parts of the body. R...

see more →

News  32 results

Dome-Shaped Periorbital Papule
https://www.mdedge.com/dermatology/article/261015/dermatopathology/dome-shaped-periorbital-papule
Adaora Ewulu, BS, Benjamin Tran, MD et. al.

Feb 3rd, 2023 - The Diagnosis: Endocrine Mucin-Producing Sweat Gland Carcinoma Endocrine mucin-producing sweat gland carcinoma (EMPSGC) is a rare cutaneous adnexal tumor that characteristically presents as slowgrowing, flesh-colored papules, nodules, or cystic le.

177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors
https://www.onclive.com/view/177lu-fap-2286-displays-preliminary-antitumor-activity-in-advanced-or-metastatic-solid-tumors

Oct 18th, 2022 - The targeted radiotherapy candidate lutetium-177-FAP-2286 (177Lu-FAP-2286) produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase ...

FDA Holds Pre-NDA Meeting to Discuss Rivoceranib Plus Camrelizumab for HCC
https://www.onclive.com/view/fda-holds-pre-nda-meeting-to-discuss-rivoceranib-plus-camrelizumab-for-hcc

Oct 12th, 2022 - Representatives from Elevar Therapeutics and the FDA held a positive pre–new drug application (NDA) meeting to discuss the combination of rivoceranib and camrelizumab as a potential therapeutic option for patients with hepatocellular carcinoma (HC...

PRMT5 Inhibitor Exhibits Efficacy and Tolerability in NHL, Advanced Solid Tumors
https://www.onclive.com/view/prmt5-inhibitor-exhibits-efficacy-and-tolerability-in-nhl-advanced-solid-tumors

Sep 12th, 2022 - GSK3326595, a PRMT5 inhibitor, displayed modest efficacy and safety signals that were consistent with those that were previously reported with the agent among patients with advanced solid tumors, according to results from the phase 1 METEOR-1 tria...

Camrelizumab/Rivoceranib Combo Significantly Improves Survival Over Sorafenib in Unresectable HCC
https://www.onclive.com/view/camrelizumab-rivoceranib-combo-significantly-improves-survival-over-sorafenib-in-unresectable-hcc

Sep 10th, 2022 - First-line treatment with camrelizumab plus rivoceranib resulted in a significant improvement in progression-free survival (PFS) and overall survival (OS) compared with sorafenib (Nexavar) in patients with unresectable hepatocellular carcinoma (HC...

see more →

Patient Education  4 results see all →